Bryn Mawr Capital Management LLC Buys 33,850 Shares of Charles River Laboratories International, Inc. (NYSE:CRL)

Bryn Mawr Capital Management LLC grew its stake in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 1,871.2% during the 4th quarter, Holdings Channel reports. The firm owned 35,659 shares of the medical research company’s stock after buying an additional 33,850 shares during the period. Bryn Mawr Capital Management LLC’s holdings in Charles River Laboratories International were worth $6,583,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently made changes to their positions in CRL. Creative Planning increased its holdings in Charles River Laboratories International by 4.0% during the third quarter. Creative Planning now owns 4,672 shares of the medical research company’s stock worth $920,000 after buying an additional 180 shares during the last quarter. Sumitomo Mitsui DS Asset Management Company Ltd increased its stake in shares of Charles River Laboratories International by 2.5% during the 3rd quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 5,818 shares of the medical research company’s stock worth $1,146,000 after purchasing an additional 141 shares during the last quarter. Blue Trust Inc. raised its holdings in shares of Charles River Laboratories International by 28.6% in the 3rd quarter. Blue Trust Inc. now owns 1,877 shares of the medical research company’s stock valued at $388,000 after purchasing an additional 418 shares during the period. Raymond James & Associates lifted its stake in Charles River Laboratories International by 0.4% in the 3rd quarter. Raymond James & Associates now owns 249,037 shares of the medical research company’s stock valued at $49,053,000 after purchasing an additional 925 shares during the last quarter. Finally, OLD National Bancorp IN grew its holdings in Charles River Laboratories International by 3.1% during the third quarter. OLD National Bancorp IN now owns 1,988 shares of the medical research company’s stock worth $392,000 after purchasing an additional 59 shares during the period. Institutional investors own 98.91% of the company’s stock.

Charles River Laboratories International Trading Up 6.9 %

Shares of CRL stock opened at $165.00 on Thursday. The stock has a market cap of $8.44 billion, a P/E ratio of 20.65, a price-to-earnings-growth ratio of 5.91 and a beta of 1.37. Charles River Laboratories International, Inc. has a 1 year low of $150.79 and a 1 year high of $275.00. The company has a current ratio of 1.48, a quick ratio of 1.14 and a debt-to-equity ratio of 0.61. The stock has a 50 day simple moving average of $174.02 and a 200 day simple moving average of $188.99.

Charles River Laboratories International (NYSE:CRL) last released its earnings results on Wednesday, February 19th. The medical research company reported $2.66 earnings per share for the quarter, beating analysts’ consensus estimates of $2.50 by $0.16. Charles River Laboratories International had a return on equity of 14.29% and a net margin of 10.44%. The firm had revenue of $1 billion during the quarter, compared to the consensus estimate of $983.63 million. During the same period in the prior year, the company posted $2.46 EPS. The company’s revenue was down 1.1% compared to the same quarter last year. On average, research analysts predict that Charles River Laboratories International, Inc. will post 10.16 earnings per share for the current fiscal year.

Analyst Ratings Changes

CRL has been the topic of several research analyst reports. UBS Group restated a “neutral” rating and issued a $185.00 price objective (down previously from $250.00) on shares of Charles River Laboratories International in a research note on Friday, January 17th. JPMorgan Chase & Co. cut their price target on Charles River Laboratories International from $215.00 to $175.00 and set a “neutral” rating for the company in a report on Monday, February 3rd. Barclays reduced their price objective on shares of Charles River Laboratories International from $205.00 to $166.00 and set an “equal weight” rating for the company in a research report on Tuesday. Evercore ISI raised their target price on shares of Charles River Laboratories International from $190.00 to $225.00 and gave the stock an “in-line” rating in a research note on Thursday, November 7th. Finally, TD Cowen lifted their target price on shares of Charles River Laboratories International from $203.00 to $227.00 and gave the stock a “hold” rating in a report on Monday, November 11th. Three equities research analysts have rated the stock with a sell rating, thirteen have given a hold rating and one has given a buy rating to the stock. Based on data from MarketBeat, Charles River Laboratories International presently has an average rating of “Hold” and an average price target of $197.64.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).